Science AI Journal
Medicine · Research topic

Open research questions in Cardiomyopathy and Myosin Studies

37 unresolved questions extracted from the limitations and future-work sections of 242 Cardiomyopathy and Myosin Studies papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Variants in alpha-actinin-2 (ACTN2), a Z-disc protein that anchors actin thin filaments have been implicated in HCM, yet their structural consequences remain poorly defined.

    Comprehensive biophysical and structural profiling of alpha-actinin-2 variants reveals mechanistic diversity in hypertrophic cardiomyopathy · 2026 · DOI

  • BackgroundNeonatal-onset hypertrophic cardiomyopathy (HCM) is a rare condition with limited data regarding clinical presentation, genetic background, and long-term outcomes.

    CLINICAL TRAJECTORY AND GENETIC LANDSCAPE OF NEONATAL-ONSET HYPERTROPHIC CARDIOMYOPATHY: INSIGHTS FROM A 30-YEAR MULTICENTER COHORT STUDY · 2026 · DOI

  • Although supervillin is implicated in actin-dependent mechanotransduction, the mechanisms linking SVIL deficiency to cardiomyopathy remain poorly understood.

    Unmasking Supervillin: SVIL haploinsufficiency causes hypertrophic cardiomyopathy by impairing mechanotransduction and cellular energetics · 2026 · DOI

  • A further limitation of this study is the incomplete availability of multimodal data across all patients. The significance of our study is limited by the diagnostic algorithm used, requiring patient reclassification according to updated guidelines at study entry. While external validation is currently lacking, this work provides a strong foundation for future studies, and validation in independent cohorts using harmonized data acquisition protocols will further enhance generalizability and enable robust pheno- typic classification and patient stratification based on EMB-derived pat- terns.

    Endomyocardial Gremlin-1 is associated with structural remodeling and adverse clinical outcomes in non-ischemic cardiomyopathy · 2026 · DOI

  • Its impact on exercise capacity, health-related quality of life and left ventricular outflow tract (LVOT) obstruction, alongside differential phenotype effects, remains incompletely characterised.

    Safety and efficacy of mavacamten in obstructive versus non-obstructive hypertrophic cardiomyopathy: a meta-analysis of randomised controlled trials · 2026 · DOI

  • While recent studies have advanced understanding of HF with preserved ejection fraction in older adults, the prevalence, outcomes and molecular drivers of diastolic HF in pediatric and young adult cardiomyopathy remain poorly defined, where disease is typically driven by primary myocardial disease rather than acquired co-morbidities.

    Rationale and Design of an Artificial Intelligence Model for Diastolic Heart Failure (AID- HF): A Canadian Cardiomyopathy Collaborative (C3) Study · 2026 · DOI

  • Centrosome duplication‐related gene play critical roles in cell cycle regulation, microtubule organization, and cellular structural homeostasis; however, their mechanistic involvement in HCM remains unclear.

    Identification of Centrosome Duplication‐Related Biomarkers in Hypertrophic Cardiomyopathy Through Integrative Multi‐Omics, Single‐Cell Transcriptomics, and Experimental Validation · 2026 · DOI

  • Future studies should investigate potential racial and ethnic differences in apical HCM prognosis. The limited number of events precluded reliable multivariable or Cox modeling, which represents an important limitation of the present study. Finally, given the differences in prevalence of apical HCM in Asian and non-Asian populations, the current findings may not be generalizable to all ethnicities.

    Implantable Cardioverter-Defibrillator Therapy in Apical Hypertrophic Cardiomyopathy: Insights From a Multicenter Study · 2026 · DOI

  • Several limitations merit consideration. First, heterogeneity in published datasets restricts direct quantitative comparison across studies. Second, publication bias may overrepresent positive mechanistic findings, potentially inflating perceived target robustness. Third, emerging modalities such as genome editing and regenerative reprogramming are evolving rapidly, and long-term safety profiles remain incompletely characterized. Fourth, the concordance scoring thresholds proposed in Table 3 are conceptual rather than empirically calibrated; validation against development outcomes across cardiomyopathy programs would strengthen their utility and permit threshold refinement. Fifth, this work does not represent a meta-analysis and does not provide pooled quantitative estimates; heterogeneity in study design, tissue 2026 Basu et al. Cureus 18(5): e108722. DOI 10.7759/cureus.108722 15 of 18 sources, analytic pipelines, and patient populations limits direct comparison across datasets. Nonetheless, structured validation remains preferable to implicit assumption, and these limitations do not undermine the core argument for concordance as a translational gate. What Evidence Would Validate This Framework? The framework presented here is conceptual. Its scoring domains, threshold values, and advancement decision rules are grounded in mechanistic reasoning and translational precedent, but they have not been empirically calibrated against historical development outcomes. Prospective validation is, therefore, a necessary next step and is explicitly acknowledged as such. Validation would require, at minimum, the following evidence base. First, independent multi-cohort human transcriptomic analyses applying the concordance scoring matrix to ClinVar-annotated cardiomyopathy genes across publicly available datasets would test whether the scoring instrument produces stable, interpretable tier classifications and whether those classifications align with mechanistically motivated expectations (e.g., lower concordance for sarcomeric contractile genes than for RNA-processing mechanism genes). Second, GTEx-benchmarked baseline variability quantification for each scored gene would confirm that the C3 domain discriminates disease signal from normal interindividual variation as theorized. Third, prospective threshold calibration against a curated dataset of cardiomyopathy development programs with known outcomes, such as advancing, stalling, or failing at each stage, would permit data-driven refinement of the 5-7 and 8-10 score cutoffs proposed in Table 3. The general principle that scoring instruments require empirical calibration against historical outcomes before their sensitivity and specificity can be characterized has been established in the context of preclinical replicability assessment [29]. Fourth, disease-generalization testing in DCM, arrhythmogenic cardiomyopathy (ARVC), and potentially non-cardiac Mendelian disorders with well-characterized transcriptomic datasets would examine whether the framework’s mechanistic stratification principle holds across pathogenic mechanism classes beyond the HCM context in which it was developed. Fifth, concordance-outcome linkage studies, which examine whether genes classified as High concordance tier by the matrix produce more reliable pharmacodynamic signals in subsequent clinical programs than genes classified as Unstable, would constitute the most direct empirical validation of the framework’s clinical utility. Until this evidence is available, the framework should be applied as a structured reasoning aid that forces explicit documentation of stability evidence, rather than as a validated predictive instrument with calibrated sensitivity and specificity. The value of its current form lies not in the precision of its scores but in the discipline it imposes on advancement decisions.

    Molecular Stability as a Translational Gate: A Structured Framework for Target Validation in Genetic Cardiomyopathy · 2026 · DOI

  • Several limitations should be acknowledged. First, the modest sample size, particularly within each disease subgroup, limits the generalizability of our findings. Second, there was no histological validation for the presence of myocardial fibrosis. In this study, LGE and ECV were used as reference biomarkers for myocardial fibrosis assessments, as they have been extensively validated against histology findings (32, 33). Third, potential confounding factors such as edema, technical artifacts, and sequence dependencies could not be fully controlled. Finally, the cross-sectional design prevents assessment of T1ρ’s ability to track disease progression or treatment response, underscoring the need for future longitudinal studies with larger cohorts and histological correlation to validate our findings and establish the clinical utility of T1ρ mapping.

    Assessment of myocardial fibrosis in ischemic and non-ischemic cardiomyopathies using cardiac magnetic resoance non-contrast T1ρ mapping · 2026 · DOI

  • This is a single case report; controlled trials with larger patient populations are needed to establish the efficacy and safety of mavacamten specifically in MVO and apical HCM phenotypes.

    Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction · 2026 · DOI

  • The claim that mavacamten therapy may be considered in patients with MVO to prevent the formation of apical ventricular aneurysms and the occurrence of sudden cardiac death lacks empirical evidence from larger prospective studies.

    Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction · 2026 · DOI

  • Limited evidence base for mavacamten in mid-ventricular obstruction (MVO); only a small phase 2 placebo-controlled trial and one recent case report exist demonstrating efficacy in this HCM phenotype.

    Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction · 2026 · DOI

  • Genetic testing is not routinely performed in clinical practice, even though there is a strong genetic component associated with LVNC, with nearly half of pediatric LVNC patients harboring an identifiable mutation.

    Clinical characteristics and short-term outcomes of left ventricular non-compaction cardiomyopathy in neonates · 2026 · DOI

  • The efficacy end point was driven by a reduction in guideline eligibility for SRT rather than the decision of patients not to proceed with SRT. Whether mavacamten can prevent other adverse outcomes favorably affected by SRT such as sudden death, cannot be assessed with the limited sample size and duration of this trial. The cur- rent study included predominantly White patients treated at high-volume HCM centers in the United States with established good outcomes for SRT procedures; and fur- ther extrapolation in different ethnicities and regions of the world may be difficult. CONCLUSIONS In highly symptomatic obstructive HCM, mavacamten treatment in patients taking maximally tolerated medical therapy reduced the long-term need for SRT with per- sistent improvements in LVOT gradients, symptoms, and quality of life. There was favorable cardiac remodeling, and the treatment was well tolerated. Because of the limited availability of high-volume SRT centers, sufficient improvement with medical therapy so that patients no longer need SRT represents a useful therapeutic option. ARTICLE INFORMATION Received September 26, 2024; accepted October 22, 2024.

    Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM · 2024 · DOI

  • At present, the prevalence of CCM remains unknown, mostly because the condition is typically latent and becomes noticeable when the patient is under stress, like exercise, drugs, hemorrhage or surgery.

    Cardiac abnormalities in hepatic cirrhosis · 2016 · DOI

  • The patterns of concentric (wall thickening / thinning) and eccentric (chamber dilation / constriction) induced by different challenges are well recognized but the underlying mechanisms remain unclear.

    Hearts may grow concentrically to balance ATP supply and demand and eccentrically to stabilize titin-based stress · 2026 · DOI

  • The interaction between MYO1B and UNC45A in intestinal epithelial morphogenesis requires deeper mechanistic characterization to understand its full biological significance.

    MYO1B in human disease: an actin-based motor linking membrane trafficking to oncogenic signaling, metastasis, and vascular aging · 2026 · DOI

  • It has been difficult to establish whether we are limited to the heart muscle cells we are born with or if cardiomyocytes are generated also later in life.

    Evidence for Cardiomyocyte Renewal in Humans · 2009 · DOI

Most-cited papers in Cardiomyopathy and Myosin Studies

Most recent work

Find a gap in your own Cardiomyopathy and Myosin Studies sub-topic

This page shows what the Cardiomyopathy and Myosin Studies literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
37 open questions have been extracted from the limitations and future-work passages of 242 Cardiomyopathy and Myosin Studies papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.